SCHEMBL1203202

SCHEMBL1203202

CCOC(=O)c1cccc(N(C)C(=O)c2cnc3ccc(NCc4ccc(F)cc4)nn23)c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NTRK1 P04629 6/20 0.46
▸ DYRK3 O43781 1/20 0.44
▸ CCNT1 O60563 1/20 0.44
▸ CCNA2 P20248 1/20 0.44
▸ CDK2 P24941 1/20 0.44
▸ CDK9 P50750 1/20 0.44
▸ CDK5 Q00535 1/20 0.44
▸ DYRK1A Q13627 1/20 0.44
▸ CDK5R1 Q15078 1/20 0.44
▸ DYRK2 Q92630 1/20 0.44
▸ DYRK1B Q9Y463 1/20 0.44
▸ FYN P06241 4/20 0.44
▸ PIM1 P11309 3/20 0.44
▸ KDM4E B2RXH2 1/20 0.41
▸ NTRK3 Q16288 3/20 0.41
▸ NTRK2 Q16620 3/20 0.41
▸ ADORA3 P0DMS8 1/20 0.40
▸ ADORA2A P29274 1/20 0.40
▸ ADORA2B P29275 1/20 0.40
▸ ADORA1 P30542 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1203715 0.91 PIM1 (0.49) NTRK1DYRK3CCNT1CCNA2CDK2
SCHEMBL1202933 0.84 NTRK1 (0.51) NTRK1DYRK3CCNT1CCNA2CDK2
SCHEMBL1203201 0.83 NTRK1 (0.47) NTRK1DYRK3CCNT1CCNA2CDK2
SCHEMBL1202066 0.83 FYN (0.56) NTRK1FYNPIM1KDM4ENTRK3
SCHEMBL1203319 0.80 PIM1 (0.62) NTRK1FYNPIM1KDM4ENTRK3
SCHEMBL1203587 0.80 DYRK3 (0.45) DYRK3CCNT1CCNA2CDK2CDK9
SCHEMBL1203703 0.76 KMT2A (0.49) NTRK1DYRK3CCNT1CCNA2CDK2
SCHEMBL1203076 0.75 PIM1 (0.51) NTRK1DYRK3CCNT1CCNA2CDK2
SCHEMBL1203713 0.75 PIM1 (0.50) NTRK1DYRK3CCNT1CCNA2CDK2
SCHEMBL1202088 0.73 FYN (0.63) NTRK1FYNPIM1KDM4ENTRK3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110046127-A1 Imidazopyridazines for Use as Protein Kinase Inhibitors CENTRO NACIONAL DE INVESTIGACIONES ONCOLOGICAS (CNIO) (ES) 2011-02-24 — — US disclosed
EP-2217601-A1 IMIDAZOPYRIDAZINES FOR USE AS PROTEIN KINASE INHIBITORS Centro Nacional de Investigaciones Oncológicas (CNIO) (ES) 2010-08-18 — — EP disclosed
WO-2009060197-A1 IMIDAZOPYRIDAZINES FOR USE AS PROTEIN KINASE INHIBITORS CENTRO NACIONAL DE INVESTIGACIONES ONCOLOGICAS (CNIO) (ES) 2009-05-14 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110046127-A1 Imidazopyridazines for Use as Protein Kinase Inhibitors PIM1, PIM3, PIM2 NTRK1 755/4885DYRK3 481/4885CCNT1 492/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback